“年少有为”还是“老当益壮”?——CEO职业生涯关注与战略变革

企业的战略变革是宏观经济转型和产业升级的重要微观基础,然而,变革活动的引领者CEO对自身职业生涯的认知会给战略变革带来怎样的影响是一个重要但仍具争议性的问题。本文整合高阶梯队理论和特质激活理论,以2007—2014年A股上市公司为样本,研究CEO职业生涯关注对战略变革的影响;采用CEO年龄和职业余期来代理CEO职业生涯关注,选择企业关键战略维度来构建战略变革的指标,对相关理论假设进行实证检验。研究发现,CEO职业生涯关注对战略变革有显著的正向影响;同时,在环境不确定性较低、经营期望落差较小、组织冗余较少以及CEO持股比例较高等组织内外部情境下,CEO职业生涯关注所能发挥的影响作用更大,对战略变革的促进效应也更为明显;进一步研究表明,在非国有企业中,CEO职业生涯关注对战略变革的影响更为显著;区分战略变革的类型,与战略变异相比,CEO职业生涯关注对战略背离的影响更为显著。本文不仅从新的视角拓展了战略变革动因的研究,而且对企业如何有效从内部驱动变革、推动企业转型发展有一定的启示意义。     

领先顾客知识管理对产品不连续创新绩效的影响

基于技术采用生命周期的视角,构建了领先顾客知识管理对企业产品不连续创新绩效影响模型,研究了战略柔性在两者间影响关系中的中介作用。利用问卷调查数据实证检验了领先顾客知识管理、产品不连续创新以及战略柔性三者之间的关系。得出如下结论:领先顾客知识管理对产品不连续创新绩效存在正向影响;战略柔性在领先顾客知识管理对产品不连续创新绩效影响中起中介作用。     

跨界搜索均衡对企业创新绩效的影响——战略柔性的调节作用

将组织均衡理论引入跨界搜索研究,构建了跨界搜索均衡对企业创新绩效影响的理论框架,实证考察了跨界搜索的匹配均衡、联合均衡及其交互作用对企业创新绩效的影响,以及战略柔性对上述影响的调节作用。基于192家高新技术企业的问卷调查数据进行实证研究。结果表明:跨界搜索的匹配均衡和联合均衡对企业创新绩效有正向影响;跨界搜索的匹配均衡和联合均衡对企业创新绩效具有正向的交互作用;战略柔性正向调节跨界搜索均衡的两个维度与企业创新绩效的关系。     

当前中国周边安全环境与战略选择

纵向观察,建国以来中国周边安全环境总体向好,但时起时伏;横向比较,当前中国周边安全环境依然严峻。当前中国周边安全环境的现状是北稳南动,西缓东急。当前中国周边安全环境面对的最大挑战有朝鲜半岛安全问题、中日钓鱼岛主权与东海划界问题、南中国海问题、美国对台军售问题,以及复杂的中印关系等。当前中国周边安全战略应继续坚持与邻为善,以邻为伴的大方针;继续坚持睦邻、友邻、安邻和富邻的周边外交政策;具体执行中采取睦北、缓西、稳南和进东战略,为中国未来10年黄金发展期创造和平安宁的周边环境。     

长株潭城市群战略性新兴产业集成创新模式研究——基于创新动因的视角

战略性新兴产业是发展低碳经济的支撑,集成创新是其创新的主导模式。通过分析战略性新兴产业的特点、现状和集成创新的优势,从创新动因角度探索了战略性新兴产业集成创新模式分为外力推动型和内力驱动型,其典型组织模式有官产学研、企业技术联盟等,其有效实施途径有建设工业园区、建设大学科技园、组建重点实验室等,并总结了长株潭城市群战略性新兴产业集成创新的成功典例。     

Interpreting IS alignment: A multiple case study in professional organizations

This paper centers on the interpretation attributed by organizational members to the information systems (IS) alignment concept. Its objective is to study IS alignment in professional organizations. Specifically, it reports on an interpretive study conducted in five Chilean organizations; four professional and one entrepreneurial, of which two are private and three are public. The theoretical background of our study is derived from three IS strategic alignment conceptualizations: managerial, emergent and critical. These concepts formed our theoretical framework that guided data collection and analysis. The study centers on the meanings organizational members assigned to IS strategic alignment, as well as their views on the barriers that hinder achieving this level of organizational integration. The analysis results are summarized in seven hermeneutic themes that point out the different connotations the organizations assigned to IS alignment. The significance of the findings are summarized in four insights that formulate theoretical and practical implications. These insights refer to: (1) the difficulties of achieving alignment for professional organizations, particularly public ones, (2) the limitations these organizations have in being agile, (3) the rationale for acquiring technology and determining IT skills, and (4) the imperative meaning that CIOs attribute to IS alignment. The paper concludes with a reflection on the limitations and relevance of the research.     

基于社会网络视角的科研合作网络结构及特性分析——以战略性新兴产业领域为例

战略性新兴产业是近几年新出现的研究热点,对其科研合作网络的研究,有助于探究该领域的科研合作现状与发展趋势。基于社会网络分析方法,以中国知网(CNKI)作为数据来源,构建了战略性新兴产业领域作者合作网络、关键词共现网络、作者-关键词耦合网络及机构合作网络,对合作网络的结构及特性等进行了分析。结果表明:战略性新兴产业领域论文合著率基本呈上升趋势,但该领域整体合作仍较为松散,存在较多的小团体;合作网络具有小世界和无标度特性,具有较大影响力的节点作为合作网络的中心,影响着网络内的学术交流和科研工作的开展。     

战略物流管理的效益模型

战略物流管理是新兴的现代管理技术 ,其中核心问题是如何提高效益。效益模型的策划和找出影响它的主要因素是本文所要解决的问题     

Converging scientific fields and new technological paradigms as main drivers of the division of scientific labour in drug discovery process: the effects on strategic management of the R&D corporate change

The thesis of this study is that the convergence of genetics, genomics and proteomics spurs new technological paradigms in medicine, which are generating a R&D corporate change: division of scientific labour of the drug discovery process by strategic alliances among firms in order to reinforce the integrative capabilities in different biomedical research fields and collective and cumulative learning between in-house R&D and external sources of innovation. This study shows, by key a case study of pharmaceutical companies, as scientific and technological paradigms in medicine are main drivers of industrial and R&D corporate change to enhance and accelerate the discovery process of ground-breaking drugs for more and more personalised healthcare.